Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo for the symptomatic treatment of seasonal allergic rhinitis: a randomized, double-blind, parallel-group study
Summary Background Bilastine is a new non‐sedative H1 receptor antagonist, indicated for the treatment of allergic rhinitis (AR) (seasonal and perennial). Objective To assess and compare the efficacy and safety of bilastine 20 mg vs. cetirizine 10 mg and placebo in relieving the symptoms of seasonal...
Gespeichert in:
| Veröffentlicht in: | Clinical and experimental allergy 2009-09, Vol.39 (9), p.1338-1347 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1347 |
|---|---|
| container_issue | 9 |
| container_start_page | 1338 |
| container_title | Clinical and experimental allergy |
| container_volume | 39 |
| creator | Kuna, P. Bachert, C. Nowacki, Z. Van Cauwenberge, P. Agache, I. Fouquert, L. Roger, A. Sologuren, A. Valiente, R. |
| description | Summary
Background
Bilastine is a new non‐sedative H1 receptor antagonist, indicated for the treatment of allergic rhinitis (AR) (seasonal and perennial).
Objective
To assess and compare the efficacy and safety of bilastine 20 mg vs. cetirizine 10 mg and placebo in relieving the symptoms of seasonal allergic rhinitis (SAR).
Methods
Overall, 683 SAR patients, aged 12–70 years, were randomized to a double‐blind treatment with bilastine 20 mg, cetirizine 10 mg or placebo, once daily for 14 days, in 61 centres across Europe. Patients recorded reflective (over the past 12 h) and instantaneous nasal (obstruction, rhinorrhoea, itching and sneezing) and non‐nasal (ocular tearing, redness and itching) symptom scores (NSS and NNSS, respectively) twice daily, according to a pre‐determined severity scale to provide reflective and instantaneous total symptom scores (TSS). The primary efficacy measure was the area under curve (AUC) of reflective TSS over 14 days of treatment (TSS‐AUC0−14 days). Secondary efficacy measures included mean change from baseline in TSS, NSS and NNSS; discomfort caused by AR; and investigator's clinical global impression of the treatment. Safety was assessed according to adverse events (AEs), laboratory tests and electrocardiograms.
Results
The mean TSS‐AUC0−14 days (score × day) was reduced in bilastine‐ and cetirizine‐treated groups to a similar and significantly greater extent, compared with placebo (76.5, 72.3 and 100.6, respectively; P |
| doi_str_mv | 10.1111/j.1365-2222.2009.03257.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_20702424</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>20702424</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4667-3ab0cd1e3b85e0ac094791b84792ab621fe93f6df0484c14c8d2a30da424cbc83</originalsourceid><addsrcrecordid>eNqNkd-K1DAUxoso7rj6CpIbvbKzSdO_ghfLMO4uLAqirHfhND2dyZg2NUnZ6V4JPppv4pOYOsN46wnkD_l9Xw75oogwumShLnZLxvMsTkItE0qrJeVJViz3j6LF6eJxtKBVlsZFWaVn0TPndpRSnlXl0-iMVSkvszJdRL_WbaskyIlA3xAHLfqJmJbUSoPzqkeS0N8_fnYbIk03gMWG3Cu_JRK9suphBtgRmA0GDRJrQ1pjid8icVM3eNOBV5J4i-A77P3s7xCc6UET0BrtJlzbreqVV-4tAWKDl-nUAzZvSGPGWmNca9WHU2hhVuh4Y804EOfHZnoePWlBO3xxXM-jL-_Xn1fX8e3Hq5vV5W0s0zwvYg41lQ1DXpcZUpC0SouK1WWYE6jzhLVY8TZvWpqWqWSpLJsEOG0gTVJZy5KfR68PvoM130d0XnTKSdQaejSjEwktaBLgAJYHUFrjnMVWDFZ1YCfBqJgDFDsx5yTmnMQcoPgboNgH6cvjG2PdYfNPeEwsAK-OADgJug1fJZU7cQkrWR5G4N4duHulcfrvBsRqfTnvgj4-6JXzuD_pwX4TecGLTNx9uBJfC86ui08rccf_AKNayx8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>20702424</pqid></control><display><type>article</type><title>Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo for the symptomatic treatment of seasonal allergic rhinitis: a randomized, double-blind, parallel-group study</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><creator>Kuna, P. ; Bachert, C. ; Nowacki, Z. ; Van Cauwenberge, P. ; Agache, I. ; Fouquert, L. ; Roger, A. ; Sologuren, A. ; Valiente, R.</creator><creatorcontrib>Kuna, P. ; Bachert, C. ; Nowacki, Z. ; Van Cauwenberge, P. ; Agache, I. ; Fouquert, L. ; Roger, A. ; Sologuren, A. ; Valiente, R. ; Bilastine International Working Group ; The Bilastine International Working Group</creatorcontrib><description>Summary
Background
Bilastine is a new non‐sedative H1 receptor antagonist, indicated for the treatment of allergic rhinitis (AR) (seasonal and perennial).
Objective
To assess and compare the efficacy and safety of bilastine 20 mg vs. cetirizine 10 mg and placebo in relieving the symptoms of seasonal allergic rhinitis (SAR).
Methods
Overall, 683 SAR patients, aged 12–70 years, were randomized to a double‐blind treatment with bilastine 20 mg, cetirizine 10 mg or placebo, once daily for 14 days, in 61 centres across Europe. Patients recorded reflective (over the past 12 h) and instantaneous nasal (obstruction, rhinorrhoea, itching and sneezing) and non‐nasal (ocular tearing, redness and itching) symptom scores (NSS and NNSS, respectively) twice daily, according to a pre‐determined severity scale to provide reflective and instantaneous total symptom scores (TSS). The primary efficacy measure was the area under curve (AUC) of reflective TSS over 14 days of treatment (TSS‐AUC0−14 days). Secondary efficacy measures included mean change from baseline in TSS, NSS and NNSS; discomfort caused by AR; and investigator's clinical global impression of the treatment. Safety was assessed according to adverse events (AEs), laboratory tests and electrocardiograms.
Results
The mean TSS‐AUC0−14 days (score × day) was reduced in bilastine‐ and cetirizine‐treated groups to a similar and significantly greater extent, compared with placebo (76.5, 72.3 and 100.6, respectively; P<0.001). Similarly, bilastine and cetirizine were comparable and significantly superior to placebo for all secondary outcomes. While all treatments were well tolerated and the AE profiles of bilastine and placebo were similar, significantly fewer patients in the bilastine‐treated group experienced somnolence (1.8%; P<0.001) and fatigue (0.4%; P=0.02) than patients in the cetirizine‐treated group (7.5% and 4.8%, respectively).
Conclusions
Bilastine 20 mg once daily was significantly superior to placebo and comparable to cetirizine 10 mg in relieving symptoms of SAR, although it demonstrated a significantly better AE profile than cetirizine.</description><identifier>ISSN: 0954-7894</identifier><identifier>EISSN: 1365-2222</identifier><identifier>DOI: 10.1111/j.1365-2222.2009.03257.x</identifier><identifier>PMID: 19438584</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Adolescent ; Adult ; Aged ; Benzimidazoles - administration & dosage ; Benzimidazoles - adverse effects ; bilastine ; Biological and medical sciences ; cetirizine ; Cetirizine - administration & dosage ; Cetirizine - adverse effects ; Child ; Double-Blind Method ; Female ; Fundamental and applied biological sciences. Psychology ; Fundamental immunology ; H1 antihistamine ; Histamine H1 Antagonists, Non-Sedating - administration & dosage ; Histamine H1 Antagonists, Non-Sedating - adverse effects ; Humans ; Male ; Medical sciences ; Middle Aged ; nasal symptoms score ; Non tumoral diseases ; non-nasal symptoms score ; Otorhinolaryngology. Stomatology ; Piperidines - administration & dosage ; Piperidines - adverse effects ; Receptors, Histamine H1 - metabolism ; Rhinitis, Allergic, Seasonal - drug therapy ; Rhinitis, Allergic, Seasonal - metabolism ; seasonal allergic rhinitis ; Time Factors ; total symptom score ; Upper respiratory tract, upper alimentary tract, paranasal sinuses, salivary glands: diseases, semeiology</subject><ispartof>Clinical and experimental allergy, 2009-09, Vol.39 (9), p.1338-1347</ispartof><rights>2009 Blackwell Publishing Ltd</rights><rights>2009 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4667-3ab0cd1e3b85e0ac094791b84792ab621fe93f6df0484c14c8d2a30da424cbc83</citedby><cites>FETCH-LOGICAL-c4667-3ab0cd1e3b85e0ac094791b84792ab621fe93f6df0484c14c8d2a30da424cbc83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1365-2222.2009.03257.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1365-2222.2009.03257.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>315,781,785,1418,27926,27927,45576,45577</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=21816161$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19438584$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kuna, P.</creatorcontrib><creatorcontrib>Bachert, C.</creatorcontrib><creatorcontrib>Nowacki, Z.</creatorcontrib><creatorcontrib>Van Cauwenberge, P.</creatorcontrib><creatorcontrib>Agache, I.</creatorcontrib><creatorcontrib>Fouquert, L.</creatorcontrib><creatorcontrib>Roger, A.</creatorcontrib><creatorcontrib>Sologuren, A.</creatorcontrib><creatorcontrib>Valiente, R.</creatorcontrib><creatorcontrib>Bilastine International Working Group</creatorcontrib><creatorcontrib>The Bilastine International Working Group</creatorcontrib><title>Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo for the symptomatic treatment of seasonal allergic rhinitis: a randomized, double-blind, parallel-group study</title><title>Clinical and experimental allergy</title><addtitle>Clin Exp Allergy</addtitle><description>Summary
Background
Bilastine is a new non‐sedative H1 receptor antagonist, indicated for the treatment of allergic rhinitis (AR) (seasonal and perennial).
Objective
To assess and compare the efficacy and safety of bilastine 20 mg vs. cetirizine 10 mg and placebo in relieving the symptoms of seasonal allergic rhinitis (SAR).
Methods
Overall, 683 SAR patients, aged 12–70 years, were randomized to a double‐blind treatment with bilastine 20 mg, cetirizine 10 mg or placebo, once daily for 14 days, in 61 centres across Europe. Patients recorded reflective (over the past 12 h) and instantaneous nasal (obstruction, rhinorrhoea, itching and sneezing) and non‐nasal (ocular tearing, redness and itching) symptom scores (NSS and NNSS, respectively) twice daily, according to a pre‐determined severity scale to provide reflective and instantaneous total symptom scores (TSS). The primary efficacy measure was the area under curve (AUC) of reflective TSS over 14 days of treatment (TSS‐AUC0−14 days). Secondary efficacy measures included mean change from baseline in TSS, NSS and NNSS; discomfort caused by AR; and investigator's clinical global impression of the treatment. Safety was assessed according to adverse events (AEs), laboratory tests and electrocardiograms.
Results
The mean TSS‐AUC0−14 days (score × day) was reduced in bilastine‐ and cetirizine‐treated groups to a similar and significantly greater extent, compared with placebo (76.5, 72.3 and 100.6, respectively; P<0.001). Similarly, bilastine and cetirizine were comparable and significantly superior to placebo for all secondary outcomes. While all treatments were well tolerated and the AE profiles of bilastine and placebo were similar, significantly fewer patients in the bilastine‐treated group experienced somnolence (1.8%; P<0.001) and fatigue (0.4%; P=0.02) than patients in the cetirizine‐treated group (7.5% and 4.8%, respectively).
Conclusions
Bilastine 20 mg once daily was significantly superior to placebo and comparable to cetirizine 10 mg in relieving symptoms of SAR, although it demonstrated a significantly better AE profile than cetirizine.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Benzimidazoles - administration & dosage</subject><subject>Benzimidazoles - adverse effects</subject><subject>bilastine</subject><subject>Biological and medical sciences</subject><subject>cetirizine</subject><subject>Cetirizine - administration & dosage</subject><subject>Cetirizine - adverse effects</subject><subject>Child</subject><subject>Double-Blind Method</subject><subject>Female</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Fundamental immunology</subject><subject>H1 antihistamine</subject><subject>Histamine H1 Antagonists, Non-Sedating - administration & dosage</subject><subject>Histamine H1 Antagonists, Non-Sedating - adverse effects</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>nasal symptoms score</subject><subject>Non tumoral diseases</subject><subject>non-nasal symptoms score</subject><subject>Otorhinolaryngology. Stomatology</subject><subject>Piperidines - administration & dosage</subject><subject>Piperidines - adverse effects</subject><subject>Receptors, Histamine H1 - metabolism</subject><subject>Rhinitis, Allergic, Seasonal - drug therapy</subject><subject>Rhinitis, Allergic, Seasonal - metabolism</subject><subject>seasonal allergic rhinitis</subject><subject>Time Factors</subject><subject>total symptom score</subject><subject>Upper respiratory tract, upper alimentary tract, paranasal sinuses, salivary glands: diseases, semeiology</subject><issn>0954-7894</issn><issn>1365-2222</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkd-K1DAUxoso7rj6CpIbvbKzSdO_ghfLMO4uLAqirHfhND2dyZg2NUnZ6V4JPppv4pOYOsN46wnkD_l9Xw75oogwumShLnZLxvMsTkItE0qrJeVJViz3j6LF6eJxtKBVlsZFWaVn0TPndpRSnlXl0-iMVSkvszJdRL_WbaskyIlA3xAHLfqJmJbUSoPzqkeS0N8_fnYbIk03gMWG3Cu_JRK9suphBtgRmA0GDRJrQ1pjid8icVM3eNOBV5J4i-A77P3s7xCc6UET0BrtJlzbreqVV-4tAWKDl-nUAzZvSGPGWmNca9WHU2hhVuh4Y804EOfHZnoePWlBO3xxXM-jL-_Xn1fX8e3Hq5vV5W0s0zwvYg41lQ1DXpcZUpC0SouK1WWYE6jzhLVY8TZvWpqWqWSpLJsEOG0gTVJZy5KfR68PvoM130d0XnTKSdQaejSjEwktaBLgAJYHUFrjnMVWDFZ1YCfBqJgDFDsx5yTmnMQcoPgboNgH6cvjG2PdYfNPeEwsAK-OADgJug1fJZU7cQkrWR5G4N4duHulcfrvBsRqfTnvgj4-6JXzuD_pwX4TecGLTNx9uBJfC86ui08rccf_AKNayx8</recordid><startdate>200909</startdate><enddate>200909</enddate><creator>Kuna, P.</creator><creator>Bachert, C.</creator><creator>Nowacki, Z.</creator><creator>Van Cauwenberge, P.</creator><creator>Agache, I.</creator><creator>Fouquert, L.</creator><creator>Roger, A.</creator><creator>Sologuren, A.</creator><creator>Valiente, R.</creator><general>Blackwell Publishing Ltd</general><general>Blackwell</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope></search><sort><creationdate>200909</creationdate><title>Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo for the symptomatic treatment of seasonal allergic rhinitis: a randomized, double-blind, parallel-group study</title><author>Kuna, P. ; Bachert, C. ; Nowacki, Z. ; Van Cauwenberge, P. ; Agache, I. ; Fouquert, L. ; Roger, A. ; Sologuren, A. ; Valiente, R.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4667-3ab0cd1e3b85e0ac094791b84792ab621fe93f6df0484c14c8d2a30da424cbc83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Benzimidazoles - administration & dosage</topic><topic>Benzimidazoles - adverse effects</topic><topic>bilastine</topic><topic>Biological and medical sciences</topic><topic>cetirizine</topic><topic>Cetirizine - administration & dosage</topic><topic>Cetirizine - adverse effects</topic><topic>Child</topic><topic>Double-Blind Method</topic><topic>Female</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Fundamental immunology</topic><topic>H1 antihistamine</topic><topic>Histamine H1 Antagonists, Non-Sedating - administration & dosage</topic><topic>Histamine H1 Antagonists, Non-Sedating - adverse effects</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>nasal symptoms score</topic><topic>Non tumoral diseases</topic><topic>non-nasal symptoms score</topic><topic>Otorhinolaryngology. Stomatology</topic><topic>Piperidines - administration & dosage</topic><topic>Piperidines - adverse effects</topic><topic>Receptors, Histamine H1 - metabolism</topic><topic>Rhinitis, Allergic, Seasonal - drug therapy</topic><topic>Rhinitis, Allergic, Seasonal - metabolism</topic><topic>seasonal allergic rhinitis</topic><topic>Time Factors</topic><topic>total symptom score</topic><topic>Upper respiratory tract, upper alimentary tract, paranasal sinuses, salivary glands: diseases, semeiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kuna, P.</creatorcontrib><creatorcontrib>Bachert, C.</creatorcontrib><creatorcontrib>Nowacki, Z.</creatorcontrib><creatorcontrib>Van Cauwenberge, P.</creatorcontrib><creatorcontrib>Agache, I.</creatorcontrib><creatorcontrib>Fouquert, L.</creatorcontrib><creatorcontrib>Roger, A.</creatorcontrib><creatorcontrib>Sologuren, A.</creatorcontrib><creatorcontrib>Valiente, R.</creatorcontrib><creatorcontrib>Bilastine International Working Group</creatorcontrib><creatorcontrib>The Bilastine International Working Group</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>Clinical and experimental allergy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kuna, P.</au><au>Bachert, C.</au><au>Nowacki, Z.</au><au>Van Cauwenberge, P.</au><au>Agache, I.</au><au>Fouquert, L.</au><au>Roger, A.</au><au>Sologuren, A.</au><au>Valiente, R.</au><aucorp>Bilastine International Working Group</aucorp><aucorp>The Bilastine International Working Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo for the symptomatic treatment of seasonal allergic rhinitis: a randomized, double-blind, parallel-group study</atitle><jtitle>Clinical and experimental allergy</jtitle><addtitle>Clin Exp Allergy</addtitle><date>2009-09</date><risdate>2009</risdate><volume>39</volume><issue>9</issue><spage>1338</spage><epage>1347</epage><pages>1338-1347</pages><issn>0954-7894</issn><eissn>1365-2222</eissn><abstract>Summary
Background
Bilastine is a new non‐sedative H1 receptor antagonist, indicated for the treatment of allergic rhinitis (AR) (seasonal and perennial).
Objective
To assess and compare the efficacy and safety of bilastine 20 mg vs. cetirizine 10 mg and placebo in relieving the symptoms of seasonal allergic rhinitis (SAR).
Methods
Overall, 683 SAR patients, aged 12–70 years, were randomized to a double‐blind treatment with bilastine 20 mg, cetirizine 10 mg or placebo, once daily for 14 days, in 61 centres across Europe. Patients recorded reflective (over the past 12 h) and instantaneous nasal (obstruction, rhinorrhoea, itching and sneezing) and non‐nasal (ocular tearing, redness and itching) symptom scores (NSS and NNSS, respectively) twice daily, according to a pre‐determined severity scale to provide reflective and instantaneous total symptom scores (TSS). The primary efficacy measure was the area under curve (AUC) of reflective TSS over 14 days of treatment (TSS‐AUC0−14 days). Secondary efficacy measures included mean change from baseline in TSS, NSS and NNSS; discomfort caused by AR; and investigator's clinical global impression of the treatment. Safety was assessed according to adverse events (AEs), laboratory tests and electrocardiograms.
Results
The mean TSS‐AUC0−14 days (score × day) was reduced in bilastine‐ and cetirizine‐treated groups to a similar and significantly greater extent, compared with placebo (76.5, 72.3 and 100.6, respectively; P<0.001). Similarly, bilastine and cetirizine were comparable and significantly superior to placebo for all secondary outcomes. While all treatments were well tolerated and the AE profiles of bilastine and placebo were similar, significantly fewer patients in the bilastine‐treated group experienced somnolence (1.8%; P<0.001) and fatigue (0.4%; P=0.02) than patients in the cetirizine‐treated group (7.5% and 4.8%, respectively).
Conclusions
Bilastine 20 mg once daily was significantly superior to placebo and comparable to cetirizine 10 mg in relieving symptoms of SAR, although it demonstrated a significantly better AE profile than cetirizine.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>19438584</pmid><doi>10.1111/j.1365-2222.2009.03257.x</doi><tpages>10</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0954-7894 |
| ispartof | Clinical and experimental allergy, 2009-09, Vol.39 (9), p.1338-1347 |
| issn | 0954-7894 1365-2222 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_20702424 |
| source | MEDLINE; Access via Wiley Online Library |
| subjects | Adolescent Adult Aged Benzimidazoles - administration & dosage Benzimidazoles - adverse effects bilastine Biological and medical sciences cetirizine Cetirizine - administration & dosage Cetirizine - adverse effects Child Double-Blind Method Female Fundamental and applied biological sciences. Psychology Fundamental immunology H1 antihistamine Histamine H1 Antagonists, Non-Sedating - administration & dosage Histamine H1 Antagonists, Non-Sedating - adverse effects Humans Male Medical sciences Middle Aged nasal symptoms score Non tumoral diseases non-nasal symptoms score Otorhinolaryngology. Stomatology Piperidines - administration & dosage Piperidines - adverse effects Receptors, Histamine H1 - metabolism Rhinitis, Allergic, Seasonal - drug therapy Rhinitis, Allergic, Seasonal - metabolism seasonal allergic rhinitis Time Factors total symptom score Upper respiratory tract, upper alimentary tract, paranasal sinuses, salivary glands: diseases, semeiology |
| title | Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo for the symptomatic treatment of seasonal allergic rhinitis: a randomized, double-blind, parallel-group study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-18T05%3A59%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficacy%20and%20safety%20of%20bilastine%2020%E2%80%83mg%20compared%20with%20cetirizine%2010%E2%80%83mg%20and%20placebo%20for%20the%20symptomatic%20treatment%20of%20seasonal%20allergic%20rhinitis:%20a%20randomized,%20double-blind,%20parallel-group%20study&rft.jtitle=Clinical%20and%20experimental%20allergy&rft.au=Kuna,%20P.&rft.aucorp=Bilastine%20International%20Working%20Group&rft.date=2009-09&rft.volume=39&rft.issue=9&rft.spage=1338&rft.epage=1347&rft.pages=1338-1347&rft.issn=0954-7894&rft.eissn=1365-2222&rft_id=info:doi/10.1111/j.1365-2222.2009.03257.x&rft_dat=%3Cproquest_cross%3E20702424%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=20702424&rft_id=info:pmid/19438584&rfr_iscdi=true |